UAB cures diabetes in lab mice, preparing for human trial
wiat.com
wiat.com
I really hope it works.
It's not a cheap drug though - about $0.75 per pill.
$0.75/pill seems like a steal.
Considering the hassles that my mom has with medicaid/medicare (not sure exactly which one it is) since the ACA with obtaining her insulin and possible cure is great news. She actually has to plan trips around shipping dates because some supplies will not ship unless X number of days passed. Worse, the costs went up. Between insulin, the pump, test strips, and mandatory examinations, its not an easy road.
These days, the costs of addition are out of control.
http://link.springer.com/article/10.1007%2FBF00626359#page-1
Nonetheless, it does seem that there have been a number of encouraging research finds around Type I diabetes in recent months (http://news.harvard.edu/gazette/story/2014/10/giant-leap-aga...).
In general, always take media coverage of scientific finds with a grain of salt, and maybe two grains for local news coverage.
At http://www.janacare.com/, we are using technology to help this process.
Any given sickness can have catastrophic effects as well. When I have a flu, I usually check myself into the hospital for monitoring. Blood sugar fluctuates hard, and its difficult to keep food down. My dad's best friend died from exactly this, a normal flu that disrupted eating patterns.
Literally ANY mistake can be life threatening. Over the last year I have been required emergency care twice due to low blood sugars. I would pay anything, do anything to have this go away.
With T1D your body stops producing insulin due to beta cell death caused by an autoimmune disorder, so you need to constantly monitor your blood glucose level and carb intake in order to dose yourself with the right amount of insulin multiple times per day, or you go into hypo/hyperglycemia.
I'm much less familiar with T2D, but I thought the body produces more and more insulin but becomes resistant and the insulin fails to adequately control blood glucose level. Beta cell death in T2D is then a follow-on confounding factor due to the persistently high glucose levels.
Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities: http://www.ncbi.nlm.nih.gov/pubmed/16306347
I really wish they had different names.
This is interesting but curing diabetes in mice has been done so many times it is hard to get too excited. It turns out mice are better at regrowing things then us.
That said i have borderline high blood pressure and am tempted to try this.
[1] in an extreme case: http://singularityhub.com/2010/05/11/the-incredible-regenera...
It may just have gone unnoticed, but there should be thousands of diabetes patients who were treated with verapamil because of high blood pressure.
http://research.jax.org/mousegenetics/advantages/advantages-...
Humans have far more variation in environment, they think relatively independently (making sticking to a prescribed regimen less likely), and they are far more complex organisms in general.
edit for other route Al Mann spent almost a billion and 20 years on inhalable insulin and only recently found success.
Also, works is a matter of interpretation. Better relative to other drugs on the market? Shows better outcomes than no treatment? There are some drugs out there that with time and more investigation are showing some lack of efficacy, eg gliptins
They also have short lives, so you don't have to wait long to see if some new treatment works.
For example, studies of type 1 diabetes usually take place in BB rats (http://en.wikipedia.org/wiki/Biobreeding_rat) or NOD mice (http://en.wikipedia.org/wiki/NOD_mice). These animals are known to exhibit the symptoms of type 1 diabetes; but we don't know if their disease progression exactly matches that of humans with type 1 diabetes (and we can't know, because we don't know exactly how type 1 diabetes progresses in humans). It's entirely possible that a cure for NOD mice simply blocks a disease pathway which doesn't occur in humans anyway.
Based on different protein targetting, the mechanism of beta-cell killing in NOD mice might not have exactly the same autoimmune interactions, and a rejuvenation strategy might not work in humans quite the same way.
It's not entirely clear to me when they plan on doing therapeutic intervention for children with Type I diabetes; by the time first symptoms show up it may be too late (unlike the mice where they knew when/that it would happen).
Finally, it's a bit odd to me that they didn't look through health records of existing type I diabetes patients that have been incidentally prescribed Verapamil. There should be some usable data that hints at the possible usefulness of this strategy, unless the patients were treated for hypertension much later in life than getting diabetes (very likely), aka too late to do anything about it.
[0]mice and rats are weird, they also have two copies of the insulin gene. One of the copies has an amino acid that is absolutely conserved across all vertebrates substituted for a substantially different one.
[1] bonus: rats also don't have gall bladders.
[2] bonus 2: While I was working on diabetes model systems in the lab, we had lots of verapamil floating around, because my boss had this crazy idea that verapimil would fix a whole category of diseases (calcium homeostasis is important for protein folding in the endoplasmic reticulum).
I noticed from the actual study that candidates for the trial must be within 3 months of diagnosis to even be considered; so it seems they are trying to screen and find only those people who have just recently developed diabetes and reverse it early in the process. In a sense this is sort of like catching a soon to be T2D in the pre-diabetic phase and telling them to eat less and run more. (There is no offense intended in that previous statement; with an obese pre-diabetic (type 2) it is possible to stop the disease before things are too late through exercise and diet, this is not the case in with a Type 1).
This makes me question if this is an effective treatment ONLY when caught early; or if it could be useful for long time diabetics like myself.
Also this treatment addresses beta cell replacement which is one side, but it doesn't address the autoimmune side which is actually causing the beta cell destruction in the first place. So would this be a lifetime pill that is taken to continuously build new beta cells? As I see it in the autoimmune T1D case as the beta cells remain under attack this would not be a "cure" per se, but rather an ongoing treatment that would result in an overall better outcome and quality of life for a diabetic (given it works at all).
If we experimented on people (tho it would take longer) we would probably find lots of things that work on people but not mice.
I say this as someone who is a proponent of the murine model. I think animal models are incredibly valuable to science and we wouldn't be where we were without them. That said, imagine all the things I described being performed on humans... I don't think that would go over so well.
A "nonfatal" lab setup wouldn't yield the same kind of results. You would be greatly limited to the scope of what you could investigate. Many experiments kill out of necessity. Also for the sake of throughput. Most of the experimental mice lines are doomed simply by the fact they lack critical immune function--we stock them that way for the sake of isolating experiments to a particular immune system function. Scientific abstraction. (And for reproducability. They're standardized equipment, if you will.)
Shouldn't you first do some open label tests and see if there appears to be any difference, and only then prove it with a double blind?
Seems like that approach would save money.
Verapamil was approved by the FDA in 1982, so I would assume safety is well established.
They're not just interested in whether T1D "goes away". If insulin requirements drop or A1c %s improve, those would also be useful results (either innately, or as a "look, there's something going on here, we just need to fine tune the dosage"). You can't get good data on those if patients' behaviour is influenced by unblinded treatment.
> I would assume safety is well established.
You can't assume that when you're dealing with smaller populations. For example, short courses of corticosteroids are very safe in the general population, but can cause life-threatening hyperglycaemia in diabetics. So they have to look for side effects; and if they're looking, they need the trial to be blinded in order to avoid seeing a side effect which doesn't really exist.
But just to belabor the point, couldn't you detect the impact on A1C or a dropping dosage pretty quickly? Everything's logged on the meter/pump/CGM, so you would have an extensive baseline to compare to....
Oh I just realized they want to test this on newly diagnosed patients. Hmmm, in that case I can see more the need for this. I wonder how much the "honeymoon" period would confound the results -- with my son we saw vast changes in required dosages throughout the first year. Not to mention it takes a while to get a handle on how to deal with it, and in the meantime... errors in handling, dosing, mis-counting carbs, etc... combined with honeymooning, I don't know how you could make heads or tails of a newly diagnosed T1D's numbers in just one year, unless the result is very significant.
I wonder why they don't test on people with well controlled T1D. I hope it doesn't imply it's something like AAT where it only possibly works if started soon after onset. I guess it's reasonable to expect early treatment after onset could be more effective, so maybe that figures into their strategy.
Typically, clinical trials occur in three phases (ref. 3). Since this drug's side effects have been studied, the researchers are moving directly to test the drug's effects.
As a final point, open label studies suffer from bias due to a person's expectations of improved health. A double-blind study minimizes this. Why spend money on a biased test that you'll need to redo instead of just doing the right test the first time?
[1] clinicaltrials.gov
[2] http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm1729...